U.S. Stock Night Market Movements
LENZ Therapeutics rose 8.54% in the night market. Based on recent news,
<ol>
<li>On December 13, LENZ Therapeutics' management stated that a patient with a history of retinal disease who had not undergone retinal examination recovered well after a right eye tear. This news boosted market confidence, driving the stock price up 8.54%. The biotechnology sector has recently performed strongly, with investor sentiment high.</li>
</ol>
Stocks with High Trading Volume in the Industry
Eli Lilly rose 1.46% in the night market. Based on recent key news:
<ol>
<li>
On December 12, Eli Lilly announced Phase 3 clinical data for Retatrutide, showing an average weight loss of 28.7% among patients, significantly higher than competitor drugs, driving the stock price up. Source: Caixin.
</li>
<li>
On December 12, JP Morgan analysts pointed out that the incidence of side effects for Retatrutide is relatively high, but still aligns with drug characteristics, targeting patients with high BMI. Source: JP Morgan.
</li>
<li>
On December 12, internal discussions at the FDA accelerated the approval process for Eli Lilly's oral weight loss drug, which may affect market expectations. Source: Reuters. Innovation in the biotech sector drives market attention.
</li>
</ol>
Tilray rose 12.18% in the night market. Based on recent key news:
<ol>
<li>
On December 13, U.S. President Trump is expected to sign an executive order to readjust the federal classification of cannabis, leading to a significant rise in cannabis-related stocks. This move will subject cannabis companies to different tax regulations and help attract investment, causing Tilray's stock price to soar over 12%. Source: CNBC.
</li>
<li>
On December 12, Tilray announced the launch of a new product line, Amped Live Resin Liquid Diamond 1g 510 cartridges, marking the Redecan brand's first entry into the liquid diamond market. This product release enhanced market confidence in Tilray, driving the stock price up. Source: MarketBeat.
</li>
<li>
On December 12, market expectations for Trump to soon sign an executive order reclassifying cannabis triggered a broad rise in cannabis concept stocks, with Tilray's stock price soaring. This news boosted investor optimism about the future of the cannabis industry. Source: CNBC. Changes in cannabis industry policies have sparked market optimism.
</li>
</ol>
Novo Nordisk fell 0.14% in the night market. Based on recent key news:
<ol>
<li>
On December 12, Novo Nordisk's semaglutide faces patent expiration pressure in China, with the rise of generic drugs potentially triggering a price war and affecting market share. (First Financial).
</li>
<li>
On December 12, the European Medicines Agency gave a positive opinion on Novo Nordisk's Wegovy 7.2 mg dosage, which may promote its market entry in the EU, enhancing market competitiveness. (First Financial)
On December 12, Novo Nordisk launched semaglutide in India. The low-price strategy may expand market coverage but also faces competitive pressure. (First Financial) The competition in the GLP-1 drug market is intensifying, and the risk of a price war is increasing
</li>
</ol>

LENZ

LENZ Therapeutics rose 8.54% in after-hours trading; Eli Lilly rose 1.46% with a trading volume of USD 1.07 million; Tilray rose 12.18% with a trading volume of USD 796,400; Novo Nordisk fell 0.14% with a trading volume of USD 346,300

U.S. stock night market volatility: Patients with retinal diseases recover well, LENZ Therapeutics surged 8.54% in after-hours trading